Please contact us using the registration form below if you wish to express interest in potentially acquiring any of Astellas’ R&D programs listed below.

  • An Astellas representative will contact you after your registration is received. (Please note that Astellas will determine the selected entity(-ies), if any, for further discussion according to the information submitted through this registration system.)
  • An Astellas representative will provide selected entities with the Confidential Disclosure Agreement (CDA) template. Please fill in the necessary information on the CDA template and send it to the Astellas representative.
     

 

＜List of divestiture programs＞
Please click on each program name for a summary (non-confidential information).

ProgramMechanism of ActionUpdate
ASP3819
Triple inhibition of ActRIIA, ActRIIB and Fn14April 2024
DRP1
Drp1 inhibitorDec. 2023
ASP1007
Bispecific T cell recruiting antibody targeting CD37-expressing cellsSep. 2022
ASP1531
Anti-Fn14 monoclonal antibodyJun. 2022

 

Registration Form

Please fill out the form and agree with the submission terms.

Company Information

Contact Information

Product(s) of interest

Attach File(s)

You can attach file(s) such as your company profile.  Do not submit any confidential or proprietary information.
Maximum 3 files.
6 MB limit.
Allowed types: gif, jpg, png, bmp, eps, tif, pict, psd, txt, rtf, html, odf, pdf, doc, docx, ppt, pptx, xls, xlsx, xml, avi, mov, mp3, ogg, wav, dmg, jar, rar, sit, svg, zip.

Submission Terms

Please agree to the following to complete this application form.  Failure to so agree renders your application as incomplete.

1. I represent and warrant that I have the authority to disclose this information and submit this application to Astellas.
2. I represent and warrant that use of the provided information will not misappropriate or infringe the intellectual property rights, or violate any other rights, of any third party.
3. I acknowledge and agree that Astellas assumes no obligation to treat the submitted information as confidential or proprietary, and thus Astellas will not be restricted from using such information or disclosing such information to third parties.
4. I acknowledge and agree that (i) there is no guarantee that Astellas will pursue an opportunity with my company or me, or that Astellas will reply to the submission; (ii) any decision to pursue an opportunity with my company or me shall be made by Astellas in its sole discretion; (iii) the solicitation by Astellas of interest in the potential acquisition of any of Astellas’ R&D programs is not an offer; and (iv) the solicitation and/or subsequent steps may be discontinued or altered, in whole or in part and as to any and all interested parties, at any time by Astellas in its sole discretion and without notice.
5. I acknowledge that I have read and agree to Astellas' Privacy Policy at https://www.astellas.com/en/privacy-notice.